For research use only. Not for therapeutic Use.
<p style=/line-height:25px/>LDN-212854 is a novel BMP inhibitor that exhibits substantially greater selectivity for BMP versus the TGF-β type I receptors; possesses a bias towards ALK2(IC50=1.3 nM) versus ALK1 and ALK3 compared to other inhibitors.<br>IC50 value: 1.3 nM [1]<br>Target: ALK2<br>In vitro, LDN-212854 exhibits some selectivity for ALK2 in preference to other BMP type I receptors, ALK1 and ALK3, which may permit the interrogation of ALK2-mediated signaling, transcriptional activity and function. LDN-212854 potently inhibits<br>heterotopic ossification in an inducible transgenic mutant ALK2 mouse model of fibrodysplasia ossificans progressiva.</p>
Catalog Number | I001671 |
CAS Number | 1432597-26-6 |
Molecular Formula | C25H22N6 |
Purity | ≥95% |
Target | TGF-βR1(ALK5) |
Solubility | DMSO: ≥ 30 mg/mL |
Storage | Store at -20°C |
IC50 | 1.3 nM [1] |
InChIKey | BBDGBGOVJPEFBT-UHFFFAOYSA-N |
Reference | <p style=/line-height:25px/> |